Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02915783 |
| Title | A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Eisai Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | United States | Details | |
| Rush University Medical Center | Chicago | Illinois | 60612 | United States | Details | |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02214 | United States | Details | |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | United States | Details | |
| Washington University | Saint Louis | Missouri | 63110 | United States | Details | |
| Weill Cornell Medical College | New York | New York | 10065 | United States | Details | |
| Texas Oncology | Dallas | Texas | 75254 | United States | Details | |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | United States | Details |